Kornimate/medical-research-clean huggingface dataset:
use of fractional co2 laser versus erbium:yag laser for the treatment of gsm in patients using aromatase inhibitors

Conditions: Genitourinary Syndrome of Menopause

Summary: to study the efficacy and safety of intravaginal co2 laser versus intravaginal er:yag laser and sham application in alleviating genitourinary symptoms in patients receiving an aromatase inhibitor as adjuvant treatment of breast cancer

the objective is to compare microablative fractional co2 laser (co2 laser) (smartxide2 v2 lr, monalisa touch; deka, florence, italy) and non-ablative photothermal erbium:yag laser (er:yag laser) (fotona smooth™ xs; fotona, ljubljana, slovenia) - with sham vaginal applications for treatment of vaginal dryness as the leading symptom in breast cancer patients with iatrogenic menopause and treated with an ai.

Eligibility criteria:
inclusion criteria: recruited participants will meet all of these criteria: * a history of breast cancer * premenopausal at diagnosis of breast cancer * using ai as an adjuvant treatment * moderate to severe symptoms of gsm (vas ≥ 4/10) * currently menopausal, which can be either biochemical menopause as confirmed after chemotherapy, surgical or medicinally induced (gnrh analogues for the duration of the trial) exclusion criteria: * not willing to abstain from vaginal intercourse for 1 week following laser therapy * use of non-hormonal vaginal preparations within the last 6 weeks before inclusion * use of hormonal therapy within 6 months prior to inclusion (systemic or local) * acute urinary or genital tract infections * a history of genital fistula, a thin rectovaginal septum as determined by the investigator, or history of fourth degree laceration * prolapse ≥ grade 2 according to the pelvic organ prolapse quantification system * previous vaginal mesh implantation * abnormal result in the last cervical smear (maximum 36 month before enrollment) * active cancer treatment (radiotherapy or chemotherapy) ongoing or planned prior to the measurement of the primary outcome (6 months after inclusion, 3 months after last laser) * vaginal stenosis that does not allow the placement of the laser probe * any condition that could interfere with study compliance

Keywords: genitourinary syndrome of menopause intravaginal laser breast cancer aromatase inhibitor
cbd (cannabidiol) intraoral application and tmd (temporomandibular disorders)

Conditions: Temporomandibular Disorder; Myofascial Pain; Orofacial Pain; CBD; Bruxism

Summary: the aim of the project is to assess the effectiveness of reducing the masseter muscles tension and hyperactivity in patients with a painful form of tmd by using polymers containing cbd compared to placebo polymers.

since the healing properties of cbd have been known for a long time, the assumption of the proposed research is to reduce the tension of the masseter muscles, reduce the bruxism index and occlusal strength, as well as reduce pain, from which patients with tmd suffer. cbd intraoral application therapy seems promising in that field. patients attending the department of tmd in zabrze, polska will be randomly divided into two groups: experimental and placebo. semg activity values will be compared during 14 and 30 days therapy with polymers. the efficacy of the cannabis cream used in the study. positive results will confirm the efficacy of cbd relaxing properties used in the study, compared to placebo.

Eligibility criteria:
inclusion criteria: * patient agreement to participate into the research study * age ≥18 and ≤ 60 * good general health, * temporomandibular disorder-positive rdc/tmd examination for group ia and ib * presence of all teeth (with the exception of the third molars) exclusion criteria: * cannabis cream/ placebo cream allergy * hypersensitivity to substances to be used in the study * wounds intra oral cavity * addiction to cannabis * patients being treated with analgesic drugs and/or drugs that affect muscle function

Keywords: temporomandibular disorder orofacial pain cbd bruxism masticatory muscles
investigation of the effectiveness of schroth exercises and pilates exercises in patients with scoliosis

Conditions: Scoliosis

Summary: the aim of this study is to examine the effectiveness of schroth exercises and pilates exercises in patients with scoliosis.

the study was planned as a randomized controlled trial. the randomization process will be done as block randomization using the random interval command in microsoft excel. the participants to be included in the study will be selected from the clients receiving consultancy services at the mehmet gümüş (mg) clinic physiotherapy and wellness center. 50 individuals diagnosed with scoliosis who applied with a postural disorder complaint will be included in the study. the individuals will be randomly divided into 2 equal groups. the rehabilitation program of the 25 individuals in the first group will be planned as 3-dimensional corrective scoliosis exercises. the program of the 25 individuals in the second group will be applied as pilates scoliosis exercises. after the initial evaluations explained to the individuals included in the study are made, an exercise program of a total of 36 sessions, each lasting approximately 50 minutes, will be applied by experienced physiotherapists who have received 3-dimensional exercise method training and pilates training specific to scoliosis, 3 days a week for 12 weeks.

Eligibility criteria:
inclusion criteria: * being between 18-45 years of age * having a primary curve between 10-40 degrees according to the cobb method * having typical s or c scoliosis * being willing to participate in the study * having the cognitive capacity to cooperate with the guidance of a physiotherapist * exclusion criteria: * having a bmi over 30 kg/m² * having any neurological, orthopedic, cardiopulmonary disorders other than the diagnosis of scoliosis * having any injuries related to the musculoskeletal system in the last 6 months * being unable to fulfill exercise requirements for any reason
effect of ursodeoxycholic acid on peritoneal function in patients on peritoneal dialysis

Conditions: End-Stage Kidney Disease

Summary: peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal dialysis (pd) for long period of time. although the exact mechanisms of peritoneal damage during pd still remain unclear, generation of endoplasmic reticulum (er) stress may be responsible for progressive membrane dysfunction. ursodeoxycholic acid (ursa) is a powerful inhibitor of er stress to protect peritoneal fibrosis in peritoneal dialysis in the investigators in-vitro study. in this study the researchers investigated the hypothesis that ursa protect peritoneal membrane damage.

ursodeoxycholic acid (ursa) is known to be relatively safe and beneficial in peritoneal dialysis patient at a dose of 300 mg per day. patients will be randomly assigned to ursa and placebo group and prescribed according to the protocol. at 2 and 6 month, peritoneal equilibrium test (pet) will be performed with blood sampling.

Eligibility criteria:
inclusion criteria: * maintenance peritoneal dialysis at least 3 months * patients who are able and willing to understand, sign and date an informed consent document, and authorize access to protected health information exclusion criteria: * episode of peritonitis at least 3 months * episodes of admission due to other disease at lease 3 months * liver disease * allergic history with ursodeoxycholic acid * nausea or vomiting after ursodeoxycholic acid

Keywords: er stress peritoneal dialysis
can the point-of-care chemistry test (poct) solve the emergency department (ed) crowding?

Conditions: Crowding

Summary: the hypothesis of this study that the point-of-care chemistry test (poct) may shorten emergency department (ed) length of stay (los).

ed crowding is one of the most serious problems in ed. poct has shorter turn-around time compared to centralized laboratory system. if poct introduce to ed, it may help to shorten los of ed patients.

Eligibility criteria:
inclusion criteria: * patients older than 15 years * clinically required to have chemistry lab tests * esi 2-5 * written agreement to participate exclusion criteria: * no agreement * esi level 1 * no chemistry lab

Keywords: crowding point-of-care systems emergency medicine
impact of sacubitril/valsartan on quality of life and mortality of ckd vs non-ckd in heart failure patients

Conditions: Heart Failure NYHA Class IV; Heart Failure NYHA Class II

Summary: the two primary goals of it's management are preventing further disease progression(mortality,hospitalizations and deterioration of left ventricular function)and alleviating patient suffering

heart failure (hf) is emerging as an epidemic in 3rd world countries. despite significant therapeutic advances, patients with chronic heart failure remain at high risk for hf progression and death. the two primary goals of its management are preventing further disease progression(mortality, hospitalizations and deterioration of left ventricular function)and alleviating patient suffering.sacubitril /valsartan (previously known as lcz696) is a first-in-class medicine that contains a neprilysin (nep )inhibitor(sacubitril) and an angiotensin ii receptor blocker (valsartan). nep is an endopeptidase that metabolizes different vasoactive peptides including natriuretic peptides, bradykinin and ang -ii. in consequence, its inhibition increases mainly the levels of both natriuretic peptides (promoting diuresis, natriuresis and vasodilation) and ang- ii whose effects are blocked by the angiotensin receptor blocker, valsartan (reducing vasoconstriction and aldosterone release).

Eligibility criteria:
inclusion criteria: 1. patients with heart failure (nyha class ii-iv). 2. lv ef(less than or equal to 40%). 3. egfr (more than 30 ml/min /1.73m2). exclusion criteria: 1. symptomatic hypotension. 2. egfr\<30 ml/min/1.73m2 . 3. serum potassium \>5.2mmol/l 4. angioedema

Keywords: chronickindeydisease, qualityoflife
low dose atropine for symptomatic vitreous floaters

Conditions: Vitreous Floaters

Summary: the objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified nei vfq-25.


Eligibility criteria:
inclusion criteria: * adult patients within prism vision group with icd diagnosis of acute posterior vitreous detachment and none of the ocular comorbidities listed as exclusion criteria will be screened as potential study participants. exclusion criteria: * patients with vitreous hemorrhage, other significant media opacity or vitreoretinal pathology, or history of pars plana vitrectomy will be excluded.
spect study with sb-773812 in schizophrenic patients

Conditions: Schizophrenia

Summary: this study is being conducted in 2 groups of schizophrenic patients: in group 1 the relationship between the dopaminergic d2 receptor occupancy (d2 ro ) and serotoninergic 5ht2a receptor occupancy at stable plasma concentration (cp) of sb-773812 will be investigated using spect scan in up to 15 chronic schizophrenic patients in an open- label design. in group 2 up to 80 patients will receive sb-773812 or risperidone for 6 weeks to obtain at least 10 patients showing clinical improvement with sb-773812. the relationship of d2 ro, measured at steady state after chronic dosing at cmax (6+/-2 h) and ctrough (24+/-4 h), and pk at steady state after repeated doses, to efficacy readouts will be investigated. the sb-773812 dose administered will be selected as the highest dose proven to be safe and well tolerated from a previous study.


Eligibility criteria:
inclusion criteria: * schizophrenic patients as diagnosed by dsm iv criteria. * in group 2, subject has schizophrenia or schizophreniform disorder and show moderate disease exacerbation, a panss score \> 65 and a score in the panss positive scale (panss-p) =25. * women of childbearing potential must agree to acceptable method of birth control. exclusion criteria: * subject shows severe exacerbation, extreme instability, high risk for suicide or serious violent behaviour. * any clinically or laboratory significant abnormality. * subjects receiving a radiation dose from other activities of more than 10 msv over any 3 year period. * subjects with organic brain disease and history of severe head trauma. * heart pacemaker, metallic prosthesis or other metallic body implants. * significant head deformity. * smokers with associated copd. * history or presence of clinically significant gastro-intestinal, hepatic or renal disease. * history of cholecystectomy or biliary tract disease. * positive for hbv, hcv or hiv. * pregnant or lactating women.

Keywords: sb-773812 spect d2 ro pharmacokinetics schizophrenic patients 5ht2a ro
heart rate variability and postoperative pain

Conditions: Pain; Postoperative

Summary: postoperative pain stimulates the autonomic nervous system, induces the production of pro-inflammatory substances, reduces patient mobility and impairs vital functions. the ecg spectral analysis (ecgs) is a non-invasive marker of the autonomic nervous system state. to our knowledge, the correlation between the sympathovagal activity quantified by a non invasive method and the postoperative pain, has not been studied before.

* principal objective : 1)to quantify postoperative pain by the ecgs technique. 2) to compare the ecgs parameters with the visual analog pain scale (vas) results. * secondary objective : to determine the influence of preoperative chronic pain and pathophysiological profiles on the correlation between postoperative ecgs and vas. * study design : an observational, prospective, single arm, single center study. * inclusion criteria : ¨patients over 18 years old scheduled for surgery under general anesthesia. patients capable of using the visual analog pain scale. * exclusion criteria : pregnancy or breast feeding, impossibility to obtain an informed consent, incapacity to follow all the study schedule. patient not protected by social security, patient likely to present hypovolemia or severe hemodynamic instability. patient with a dysautonomia characterized by orthostatic hypotension, patients with cardiac disarrhythmias, likely to interfere with the ecg and/or the spectral analysis of ecg. * study plan: patients will sign their informed consent during the v0 visit (preoperative). during v0, hf and lf (ecgs parameters) will be measured as well as the vas-estimated pain. these results, medical history, concomitant diseases and medications will be reported in a case report form (crf). the second and last visit, v1, takes place 1 hour after the patient wakes up, in the postoperative period. ecgs and vas evaluation will be achieved in the same manner as the v0 visit. the only difference is that the measurements will be repeated to obtain a total of 5 data couples over 2 hours. these intrapatient estimations will be used to improve statistical ecgs vs vas correlation analysis. * number of subjects : 100

Eligibility criteria:
inclusion criteria: * patients over 18 years old scheduled for surgery under general anesthesia. * patient able to use the visual analog pain scale exclusion criteria: * pregnancy or breast feeding * impossibility to obtain an informed consent * incapacity to follow all the study schedule * patient not protected by social security * patient likely to present hypovolemia or severe hemodynamic instability * patient with a dysautonomia characterized by orthostatic hypotension * patient with cardiac disarrhythmias, likely to interfere with the ecg and/or the spectral analysis of ecg

Keywords: postoperative pain heart rate variability, sympathetic, parasympathetic visual analog pain scale spectral analysis of ecg
acupuncture for mucositis pain in cancer care

Conditions: Mucositis; Pain; Leukemia

Summary: this research is being done to see if acupuncture helps relieve mucositis pain in patients with leukemia who are undergoing chemotherapy. many patients receiving chemotherapy develop mucositis (painful sores or blisters in the mouth or throat). mucositis is not only a frequent complication in cancer care and extremely painful, but also increases the risks of infection and malnutrition and often leads to discontinuing or delaying the chemotherapy treatments.

acupuncture is one of the oldest, most commonly used medical procedures in the world. the practice originated in china more than 2,000 years ago, and is widely used by doctors in korea, china, japan, and other countries to ease pain or various symptoms. in the past two decades, acupuncture has grown in popularity in the united states, and by 2002, an estimated 8.2 million adults in the us report having used acupuncture. the term acupuncture describes a family of procedures involving stimulation of anatomical points on the body by a variety of techniques. the acupuncture technique that has been most studied scientifically involves penetrating the skin with thin, solid, metallic needles that are manipulated by the hands or by electrical stimulation. acupuncture needles are metallic, solid, and hair-thin. people experience acupuncture differently, but most feel no or minimal pain as the needles are inserted. some people are energized by treatment, while others feel relaxed. acupuncture has been used to ease some cancer treatment-related side effects such as nausea and vomiting. in this study we will assess the potential usefulness of acupuncture to ease the pain associated with mucositis.

Eligibility criteria:
inclusion criteria: * newly diagnosed with leukemia (such as acute myelogenous leukemia) and receiving chemotherapy for induction, consolidation or re-induction or high dose preparative regimen for bone marrow transplantation in the johns hopkins oncology inpatient services * participation in standard leukemia-treatment regimens * expectation of survival of three weeks for completion of the study exclusion criteria: * acupuncture treatment within the previous 6 weeks * unable to achieve platelet count of at least 10,000 with platelet support * radiation therapy within one month of enrollment * pregnant women * history of substance abuse, including alcohol and iv drug users

Keywords: mucositis pain cancer pain acupuncture mucositis cancer pain
macular buckle with three-armed silicone

Conditions: High Myopia; Posterior Staphyloma

Summary: high myopia is characterized by prolonged axial length and posterior staphyloma, which result in choroid-retinal degeneration and vision decrease. at present, vitrectomy can lead to anatomical improvements, but an higher axial length and the presence of a sever posterior staphyloma remains to be the two most important risk factors for poor visual outcomes. for these reasons, a different surgical approach, including macular buckling, might be considered in those patients with extremely high degree of myopia, in order to counteract the traction exerted by the posterior staphyloma. macular buckling with or without pars plana vitrectomy had been proved to be an effective way to resolve myopic staphyloma related foveoschisis, macular hole, and associated retinal detachment. in this study, we sought to investigate the safety and efficacy of a macular buckling technique using a three-armed silicone capsule to support the posterior staphyloma in high myopia.

1. this study plans to recruit 11 participants with 6 months follow-up to assess the safety and efficacy of a newly designed macular buckle device; 2. the macular buckle device, surgical procedure, and participants registry had been reviewed and approved by ethics committee of zhongshan ophthalmic center; 3. only those patients are diagnosed with severe posterior staphyloma are registered. 4. all participants are fully informed before register; 5. all the surgeries are performed by single qualified doctor (lin lu); 6. after operation, all participant could contact the researcher via telephone, and could be assessed for any surgical related complications. if there is severe complication happened, or any person that could not tolerant the macular buckle, the implanted device will be removed; 7. specially assigned staff (jinge lu) is responsible for data collection, data management, adverse events reporting, and participant communication.

Eligibility criteria:
inclusion criteria: * high myopia over -8.0 diopter * axial length over 26.5 mm * posterior staphyloma exclusion criteria: * single eye patients * retinal detachment beyond macular area * a history of posterior scleritis * a history of glaucoma * active hemorrhage in the surgical eye * active inflammation in the surgical eye * any situation that might hinder the observation of macular

Keywords: macular buckle high myopia posterior staphyloma
visual attention span mobilisation for dyslexia

Conditions: Dyslexia; Visual Attention Span Deficit

Summary: the aim of the study is to evaluate the efficiency of the medical device maevad in improving the reading skills of children with dyslexia.

maevad is a digital therapy specifically designed to improve the visual attention (va) span of children with dyslexia. dyslexia is characterized by a specific and significant impairment in reading and/or writing production and spelling. some profiles of children with dyslexia show a deficit in va span, characterized by a decrease in the number of distinct visual elements that can be processed simultaneously. va span plays a critical role in the acquisition of reading skills and specific knowledge of word spelling. brain regions involved in visual-attentional skills are under-activated in dyslexic children with va deficits and can be reactivated following specific and intensive va span training. in this study 150 children with dyslexia will be randomized in tow groups. on the first group children will be trained first with maevad then with a control training that does not stimulate the va span. on contrary, on the second group children will first perform the control training and then maevad. for each intervention the sessions will lasts 15 minutes. 5 sessions are planned per weeks for 6 weeks.

Eligibility criteria:
inclusion criteria: * school children from ce2 to cm2, aged 8 to 11 years * dyslexic children with a va span deficit (composite visual-attention span below the fifteenth percentile and a letter threshold above or equal to the twentieth percentile with the - - - evadys(c) battery) * established diagnosis of dyslexia * children whose parents/legal guardians have signed informed consent and agree to participate in the study * children whose first language is french or who have been educated in french since kindergarten * raven's progressive matrices score above the 20th percentile or a wisc iv or v verbal comprehension index or wisc iv or v perceptual/fluid reasoning index above 85 or documented/objectifiable absence of intellectual deficit * child with access to a computer * normal or corrected vision and audition exclusion criteria: * attention deficit hyperactivity disorder,dysphasia, dyspraxia, autism spectrum disorder * neurological disorders * children who have missed 3 months or more of school in the current or previous year (excluding lockdown) * children not affiliated to a social security scheme

Keywords: maevad maeva reading remediation visual attention span